Dermatology

Login Register

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Parthika Patel

M. Pharm (Pharmaceutics)

Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Home

Parthika Patel

Articles By : Parthika Patel

CDSCO Clears Abbott's phase IV Trial Of Dydrogesterone MR Tablet

Parthika Patel30 Jun 2025 2:53 PM IST

New Delhi: The Subject Expert Committee (SEC) under the Reproductive division of the Central Drugs Standard Control Organization (CDSCO) has approved...

Pfizer Gets CDSCO Panel Nod to Conduct Phase IIIb Trial of Rimegepant for Menstrual Migraine

Parthika Patel28 Jun 2025 7:23 PM IST

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organisation (CDSCO) has granted Pfizer Limited...

CDSCO Asks Serum Institute to Revise Protocol for Trivalent Flu-COVID Vaccine Trial

Parthika Patel27 Jun 2025 10:53 PM IST

New Delhi: The Subject Expert Committee (SEC) under the COVID-19 division of the Central Drugs Standard Control Organization (CDSCO) has reviewed a...

SEC Clears Hemopurifier Device for Cancer Study in Indian Patients

Parthika Patel26 Jun 2025 7:50 PM IST

New Delhi: In a step toward advancing medical device-based cancer care, the Subject Expert Committee (SEC) under the Oncology division of the Central...

Label Update for AstraZeneca's Olaparib Cleared by CDSCO Panel

Parthika Patel25 Jun 2025 5:11 PM IST

New Delhi: In a recent regulatory update, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard Control...

SEC Recommends Market Authorization for Elobixibat 5 mg Tablets by Exemed Pharma

Parthika Patel22 Jun 2025 10:00 AM IST

New Delhi: The Subject Expert Committee (SEC) under the Gastroenterology and Hepatology division of the Central Drugs Standard Control Organization...

Sun Pharma Gets Relief on Packaging Norms for Pantoprazole-Levosulpiride FDC

Parthika Patel21 Jun 2025 4:18 PM IST

New Delhi: In a regulatory relief to the company, the Subject Expert Committee (SEC) under the Gastroenterology and Hepatology division of the Central...

Mankind Pharma Gets CDSCO Panel Nod to Conduct Phase III Trial of Resmetirom Tablets

Parthika Patel21 Jun 2025 11:45 AM IST

New Delhi: The Subject Expert Committee (SEC) under the Gastroenterology and Hepatology division of the Central Drugs Standard Control Organisation...

CDSCO Panel Rejects Phase II Data for Reliance's RelCoVax COVID-19 Booster Over Immunogenicity Gap

Parthika Patel19 Jun 2025 7:53 PM IST

New Delhi: The Subject Expert Committee (SEC) on COVID-19 vaccines, operating under the Central Drugs Standard Control Organisation (CDSCO), has...

Exemed's Sitagliptin FDC Hits Roadblock as CDSCO Panel Flags No Added Safety Benefit

Parthika Patel18 Jun 2025 5:53 PM IST

New Delhi: In a setback for Exemed Pharmaceutical, the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO)...

Fresenius Told to Submit Global Data for Calcium Chloride Infusion Approval

Parthika Patel18 Jun 2025 4:36 PM IST

New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has asked Fresenius Medical Care India...

Intas Gets CDSCO Panel Nod to Conduct Phase III Trial of Semaglutide Injection for Weight Management

Parthika Patel17 Jun 2025 6:30 PM IST

New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has accepted the Bioequivalence (BE)...

Journal Club Today

Health News Today

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok